Retham Technologies, Inc.
Retham is developing HITDx, a functional hospital-lab assay for heparin-induced thrombocytopenia that uses stable cryopreserved donor platelets to make clinically relevant platelet testing more practical; the diagnostic is in validation and regulatory development, while its cryopreserved platelets are available for research use.
$1.5MSeed
Participant